

**APC anti-human CD267 (TACI)**

**Catalog # / Size:** 2159555 / 25 tests  
2159560 / 100 tests

**Clone:** 1A1

**Isotype:** Rat IgG2a, κ


**Immunogen:** TACI-transfected RBL cells

**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Concentration:** 0.2




Human peripheral blood lymphocytes were stained with CD19 FITC and CD267 (clone 1A1) APC (top image) or rat IgG2a, κ APC isotype control. (bottom image).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application References:** 1. Ng LG, *et al.* 2004. *J. Immunol.* 173:807. (FC)  
2. Lougaris V, *et al.* 2012. *Hum Immunol.* 73:836. [PubMed](#).

**Description:** TACI, Transmembrane Activator CAML (calcium modulator and cyclophilin ligand) Interactor, is a 32 kD type III transmembrane protein. It belongs to TNF receptor

superfamily, known as TNFRSF member 13B (TNFRSF13B) or CD267. TACI is expressed on B cells, and myeloma cells. TACI contains 2 cysteine-rich domains (CRDs). Recent studies, however, have shown that another shorter form (TACI\_d2) of TACI exists wherein the N-terminal CRD is removed by alternative splicing. TACI\_d2 contains full affinity for its ligands. Several proteins (BAFF/BLys, APRIL, Syndecan-2) have been identified as TACI ligands. The interaction of TACI with its ligands induces activation of the transcription factors NFAT, AP1, and NF- $\kappa$ B and plays a crucial role in humoral immunity by negative regulation of B cell proliferation and survival.

**Antigen  
References:**

1. Gross JA, *et al.* 2000. *Nature* 404:995.
2. Wu Y, *et al.* 2000. *J. Biol Chem.* 275:35478.
3. Yan M, *et al.* 2001. *Nat. Immunol.* 2:638.
4. Hymowitz A, *et al.* 2005. *J. Biol.*